drugset / Trial / NCT05278962
HF Patients With LVADs Being Treated With SGLT2i
RandomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of this study is to observe outcomes of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in heart failure (HF) patients with left ventricular assist devices (LVAD).
Timeline
- Start
- 2022-09-08
- Primary completion
- 2025-08-31
- Completion
- 2025-08-31
Outcome
Missed primary endpoint
registry analysis (other test); SGLT2i vs No SGLT2i; p = 0.38; Wilcoxon (Mann-Whitney) NCT05278962 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dapagliflozin | Small molecule | 10 mg | — |
| Subject | Empagliflozin | Small molecule | 10 mg | — |
Indications
No indication recorded.